KA (Kineta, Inc.) שווי פירמה כולל

Kineta, Inc. (KA) research centers develop monoclonal antibodies, outsourcing the mass production of candidates to external biopharmaceutical plants. However, international trials and the implementation of new therapies are being hindered by political isolation and diplomatic ruptures. This chart from GURU.Markets shows an Enterprise Value of , while the diversification of raw material suppliers helps the business maintain high research profitability.

The prospects for Kineta, Inc. (KA) are based on future successes in immuno-oncology, while the absence of current revenue renders the business valuation speculative. By analyzing the historical enterprise value chart—calculated as the sum of market capitalization and debt minus cash—an investor can determine the actual acquisition price of the asset, making it possible to identify an overvaluation of the company in the absence of commercial income.